Second-line treatment paradigms for diffuse large B-cell lymphomas.
Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant proportion of patients will experience early treatment failure, partial response, or relapse after initial chemotherapy. For more than 10 years, the standard treatment for chemosensitive relapses has been based on salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation in selected patients. However, several important questions remain: What is the best salvage regimen? What is the efficacy of rituximab in an era when R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is accepted as standard care for frontline therapy? What are the risk factors in second-line therapy? What is the best treatment when high-dose therapy and autologous stem cell transplantation are not possible? This article reviews all these issues and discusses new biologic therapies, with the knowledge that improvements in outcome may be achieved through a greater understanding of the biologic parameters associated with poorer prognosis.
Thieblemont
Catherine
C
Hôpital Saint Louis, Hemato-Oncologie, Institut Universitaire d'Hématologie, 1 Avenue Claude Vellefaux, 75010 Paris, France.
Gisselbrecht
Christian
C
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D016019:Survival Analysis; D014750:Vincristine
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Cancer Biother Radiopharm. 2007 Feb;22(1):113-20
17627419
Oncology. 2005;69(6):499-502
16424679
Haematologica. 2006 Jan;91(1):114-20
16434379
J Clin Oncol. 2005 Jun 20;23(18):4117-26
15867204
Bone Marrow Transplant. 2007 Dec;40(11):1007-17
17922042
Exp Hematol. 2007 Apr;35(4):534-40
17379063
Ann Oncol. 2006 May;17 Suppl 4:iv31-2
16702182
N Engl J Med. 1995 Dec 7;333(23):1540-5
7477169
Leuk Lymphoma. 2007 Apr;48(4):708-15
17454628
Leuk Lymphoma. 2006 Dec;47(12):2558-66
17169800
Haematologica. 2008 Dec;93(12):1829-36
18945747
Cancer Sci. 2006 Sep;97(9):933-7
16805825
Blood. 2004 May 15;103(10):3684-8
14739217
J Med Chem. 2008 Nov 13;51(21):6902-15
18841882
Leuk Lymphoma. 2005 Jan;46(1):71-5
15621783
Blood. 1998 Nov 15;92(10):3562-8
9808548
Ann Oncol. 2007 Aug;18(8):1363-8
17496309
J Clin Oncol. 2007 May 1;25(13):1741-6
17389337
Nat Rev Cancer. 2005 Apr;5(4):275-84
15803154
Blood. 2004 Feb 1;103(3):777-83
12907446
Blood. 2008 Feb 15;111(4):2230-7
18006696
Ann Hematol. 2007 Apr;86(4):271-6
17216473
Br J Haematol. 2001 Dec;115(4):786-92
11843810
Am J Hematol. 2009 Feb;84(2):93-7
19123458
Blood. 2004 Aug 1;104(3):634-41
15016643
Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16
19219604
J Clin Oncol. 2008 Jan 1;26(1):90-5
18025438
Ann Oncol. 2006 May;17 Suppl 4:iv18-24
16702180
J Clin Oncol. 2006 Aug 20;24(24):3880-6
16864854
N Engl J Med. 2002 Jan 24;346(4):235-42
11807147
Eur J Haematol. 2008 Feb;80(2):127-32
18005385
J Clin Oncol. 1992 Oct;10(10):1615-23
1383435
Oncol Rep. 2003 Nov-Dec;10(6):1915-7
14534718
J Clin Oncol. 1998 Oct;16(10):3264-9
9779700
Blood. 2008 Jan 15;111(2):537-43
17971487
J Clin Oncol. 2005 Apr 1;23(10):2240-7
15800314